Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
17-DMAG
CHF 40.00
In stock
BVT-0255-C100100 µgCHF 40.00
BVT-0255-M0011 mgCHF 70.00
| Product Details | |
|---|---|
| Synonyms | NSC 707545; 17-[2-(Dimethylamino)ethyl]amino-17-desmethoxygeldanamycin |
| Product Type | Chemical |
| Properties | |
| Formula | C32H48N4O8 |
| MW | 616.8 |
| CAS | 467214-20-6 |
| Source/Host Chemicals | Semi-synthetic derivative from geldanamycin. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Purple to black powder. |
| Solubility | Soluble in water, 100% ethanol (10 mg/ml) or DMSO (>25 mg/ml) |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by BioViotica. |
| InChi Key | KUFRQPKVAWMTJO-LMZWQJSESA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light when in solution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. After reconstitution protect from light at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Less toxic, more potent synthetic derivative of geldanamycin (Prod. No. BVT-0196).
- Angiogenesis inhibitor.
- Heat shock protein 90 (HSP90) inhibitor.
- Apoptosis inducer.
- Shows higher antitumor activity than 17-AAG (Prod. No. BVT-0244).
Product References
- Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats: M.J. Egorin, et al.; Cancer Chemother. Pharmacol. 49, 7 (2002)
- Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats: S.M. Musser, et al.; Cancer Chemother. Pharmacol. 52, 139 (2003)
- Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90: J.M. Jez, et al.; Chem. Biol. 10, 361 (2003)
- Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator: G. Kaur, et al.; Clin. Cancer Res. 10, 4813 (2004)
- Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin: E.E. Bull, et al.; Clin. Cancer Res. 10, 8077 (2004)
- Synthesis and biological activities of novel 17-aminogeldanamycin derivatives: Z.Q. Tian, et al.; Bioorg. Med. Chem. 12, 5317 (2004)
- Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models: V. Smith, et al.; Cancer Chemother. Pharmacol. 56, 126 (2005)
- In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative: M. Hollingshead, et al.; Cancer Chemother. Pharmacol. 56, 115 (2005)
- Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance: E.R. Glaze, et al.; Cancer Chemother. Pharmacol. 56, 637 (2005)
- Structure-based design of 7-carbamate analogs of geldanamycin: G. Rastelli, et al.; Biooorg. Med. Chem. Lett. 15, 5016 (2005)
- Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry: K. Hwang, et al.; J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 35 (2006)
Related Products
